Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2
Authors:
Open Access
- 23 May 2022
- journal article
- other
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 11 (1) , 1371-1389
Abstract
Currently, SARS-CoV-2, especially the Omicron strain, is ravaging the world and even co-infecting human beings with IAV, which is a serious threat to human public health. As of yet, no specific antiviral drug has been discovered for SARS-CoV-2. This requires deeper understandings of the molecular mechanisms of SARS-CoV-2-host interaction, to explore antiviral drug targets and provide theoretical basis for developing anti-SARS-CoV-2 drugs. This article discussed IAV, which has been comprehensively studied and is expected to provide the most important reference value for the SARS-CoV-2 study apart from members of the Coronaviridae family. We wish to establish a theoretical system for the studies on virus-host interaction. Previous studies have shown that host PRRs recognize RNAs of IAV or SARS-CoV-2 and then activate innate immune signaling pathways to induce the expression of host restriction factors, such as ISGs, to ultimately inhibit viral replication. Meanwhile, viruses have also evolved various regulatory mechanisms to antagonize host innate immunity at transcriptional, translational, post-translational modification, and epigenetic levels. Besides, viruses can hijack supportive host factors for their replication. Notably, the race between host antiviral innate immunity and viral antagonism of host innate immunity forms virus-host interaction networks. Additionally, the viral replication cycle is co-regulated by proteins, ncRNAs, sugars, lipids, hormones, and inorganic salts. Given this, we updated the mappings of antiviral drug targets based on virus-host interaction networks and proposed an innovative idea that virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2 from the perspectives of viral immunology and systems biology.Keywords
Funding Information
- National Key Research and Development Programme of China (2021YFD1800205)
- National Natural Science Foundation of China (31772775)
- State Key Laboratory of Veterinary Biotechnology (SKLVBF202103)
- the Specialized Fund for the Basic Research Operating Expenses Programme of Central College (KYZ201726)
- the Priority Academic Programme Development of Jiangsu Higher Education Institutions (PAPD)
This publication has 80 references indexed in Scilit:
- Glycolytic control of vacuolar-type ATPase activity: A mechanism to regulate influenza viral infectionVirology, 2013
- Adding Protein Context to the Human Protein-Protein Interaction Network to Reveal Meaningful InteractionsPLOS Computational Biology, 2013
- Species-Specific Inhibition of RIG-I Ubiquitination and IFN Induction by the Influenza A Virus NS1 ProteinPLOS Pathogens, 2012
- Cellular microRNA let‐7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cellsJournal of Cellular and Molecular Medicine, 2012
- Intrinsic antiviral immunityNature Immunology, 2012
- The host interactome of influenza virus presents new potential targets for antiviral drugsReviews in Medical Virology, 2011
- PB2 and Hemagglutinin Mutations Are Major Determinants of Host Range and Virulence in Mouse-Adapted Influenza A VirusJournal of Virology, 2010
- Cellular MicroRNAs Inhibit Replication of the H1N1 Influenza A Virus in Infected CellsJournal of Virology, 2010
- Influenza A Virus NS1 Targets the Ubiquitin Ligase TRIM25 to Evade Recognition by the Host Viral RNA Sensor RIG-ICell Host & Microbe, 2009
- Influenza A Virus Inhibits Type I IFN Signaling via NF-κB-Dependent Induction of SOCS-3 ExpressionPLOS Pathogens, 2008